News

May 14, 2012 – Endosense said there has been strong interest and significant advancement in the move toward making contact-force sensing a standard-of-care in catheter ablation procedures. Participating at the Heart Rhythm (HRS) 2012 meeting last week in Boston, the company noted a wealth of new clinical abstracts and a new HRS/EHRA/ECAS consensus statement as key validation points supporting the value of the sensory parameter in cardiac ablation.

Home May 14, 2012
Home
News

May 14, 2012 ? Boston Scientific Corp. announced extended warranties of up to 10 years, depending on the model, for its Energen and Incepta implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The company said the new warranty program is the longest available in the industry and provides physicians, patients and payers across Europe warranties up to five years longer than other currently-marketed cardiac devices. Following are the devices and their warranties.

Home May 14, 2012
Home
News

Sorin Group announced at the Heart Rhythm Society (HRS) annual scientific sessions, the publication of the CLEAR study results in Europace (May 1, 2012, doi:10.1093/europace/eus059). The study demonstrates the clinical benefit of the SonR sensor based cardiac resynchronization therapy (CRT) optimization system in heart failure (HF) patients.

Home May 14, 2012
Home
News

May 14, 2012 -- Two types of stent systems are both effective in treating patients who have severe forms of peripheral artery disease (PAD), according to results of the MOBILITY trial presented today as a late-breaking clinical trial at the SCAI 2012 Scientific Sessions.

Home May 14, 2012
Home
News

May 14, 2012 – A retrospective analysis of data from the OMNI Registry, a large-scale, longitudinal registry of nearly 3 ...

Home May 14, 2012
Home
News

May 14, 2012 — Boston Scientific announced results from the ASA Plavix (ASAP) Study, which studied the Watchman Left Atrial Appendage (LAA) Closure device. The data showed a reduction in the risk of ischemic stroke by 75 percent in patients with atrial fibrillation who have a contraindication to oral anticoagulants such as warfarin.

Home May 14, 2012
Home
News

May 14, 2012 -- Heart attack patients in North Carolina who were rushed directly to hospitals equipped to do percutaneous coronary intervention (PCI) received treatment significantly faster than patients first taken to hospitals unequipped to perform PCI and then later transferred for treatment, according to research reported at the American Heart Association's Quality of Care and Outcomes Research 2012 Scientific Sessions.

Home May 14, 2012
Home
Technology

The new irrigated ablation catheter combines Biosense Webster’s latest porous tip technology with the accurate visualization of the Carto3 3-D mapping and ablation system. This enhanced technology is designed to reduce fluoroscopy exposure to physicians, lab staff and patients alike, enhance visualization of the ablation catheters orientation and improve procedural efficiency.

Home May 14, 2012
Home
Technology

May 14, 2012 - LifeWatch, a cardiac monitoring service provider, has launched a strategic alliance with Perminova, a developer of Web-based information systems for cardiology centers, to expand interoperability between medical monitoring devices and information technology in cardiac electrophysiology.

Home May 14, 2012
Home
News

May 14, 2012 – The Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS) release the "PACES/HRS Expert Consensus Statement on the Management of the Asymptomatic Young Patient with a Wolff-Parkinson-White (WPW, Ventricular Pre-Excitation) Electrocardiographic Pattern." The expert consensus statement presented at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific Sessions, provides first-of-its-kind clinical practice guidelines on the evaluation and management of asymptomatic young patients with a WPW electrocardiographic pattern. This is also the first collaboration between PACES and HRS.

Home May 14, 2012
Home
News

Initial results from the international Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS (EFFORTLESS) subcutaneous implantable defibrillator (S-ICD Registry shows that the latest heart device, the S-ICD system, is performing appropriately in real-world circumstances and continues to show positive results in patients. This data is was presented for the first time at the Heart Rhythm Society (HRS) annual scientific sessions in Boston.

Home May 14, 2012
Home
Feature

A study of more than 350 competitive athletes with implantable cardioverter defibrillators (ICDs) from around the world showed for the first time that sports may be safer for this group than has been thought. There were no occurrences of death or injury due to arrhythmia or shock during sports in this group. Additionally, only 10 percent of the athletes received a shock during competition or practice and of those, most continued to play, as reported at the Heart Rhythm Society (HRS) scientific sessions in Boston.

Home May 14, 2012
Home
News

May 11, 2012 — A new report issued this week by the American College of Cardiology Foundation (ACCF) and the Society for Cardiovascular Angiography and Interventions (SCAI), in collaboration with a dozen other professional societies, provides detailed criteria to help clinicians determine when cardiac catheterization is a reasonable option for the evaluation of patients for heart disease.

Home May 11, 2012
Home
Feature

May 11, 2012 — Modern cardiac catheterization laboratories bear scant resemblance to the cath labs of a decade ago. An updated consensus statement released this week offers physicians guidance on how to excel in this new diagnostic and therapeutic milieu, with specific recommendations on setting up, operating and maintaining the highest standards of quality in a contemporary cardiac cath lab.

Home May 11, 2012
Home
Technology

May 11, 2012 — The Sorin Group is launching new implantable devices with a proprietary algorithm system as well as three leads, and releasing data showing improved patient outcomes with a novel CRT (cardiac resynchronization therapy) optimization system. The company highlighted this news during the Heart Rhythm Society 2012 meeting this week in Boston.

Home May 11, 2012
Home
Subscribe Now